mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma

被引:8
作者
Han, Ke [1 ]
Zhang, Yi [1 ]
机构
[1] Capital Med Univ, Dept Thorac Surg, Xuan Wu Hosp, Beijing 100053, Peoples R China
关键词
Epidermal growth factor receptor; programmed cell death ligand 1; phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway; lung adenocarcinoma; PHOSPHOINOSITIDE; 3-KINASES; CANCER; PD-L1; ASSOCIATION; ACTIVATION; ANTIBODY; SAFETY;
D O I
10.4103/jcrt.JCRT_636_18
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objective: The objective of this study is to investigate the relationship between programmed cell death ligand 1 (PD-L1) expression and the mutation status of epidermal growth factor receptor (EGFR) in lung adenocarcinoma, as well as the correlation between the clinical features of patients and mRNA levels of PD-L1 and components of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/phosphatase and tensin homolog (PTEN) pathways. Methods: mRNA levels of PD-L1, PI3K, AKT, and PTEN in tumor and matched normal tissues of patients with EGFR mutation-positive lung adenocarcinoma were determined by real-time polymerase chain reaction. Results: Twenty-three patients with EGFR mutation-positive lung adenocarcinoma were enrolled, and 46 samples (23 pairs of tumor and matched normal lung tissues) were collected. PD-L1 and AKT mRNA levels were higher in EGFR mutation-positive lung adenocarcinoma than in matched normal lung tissues (P = 0.047 and P = 0.046, respectively), whereas PI3K and PTEN mRNA levels were significantly lower in the cancerous tissues (P = 0.009 and P = 0.039, respectively). PD-L1 expression was positively correlated with PI3K/AKT signaling pathway activation. PD-L1 upregulation in lung adenocarcinoma was positively correlated with EGFR exon 19 mutations (P = 0.034). AKT mRNA upregulation was correlated with lymph node metastasis (P = 0.034). PTEN mRNA downregulation was correlated with high tumor staging and lymph node metastasis (P = 0.035 and P = 0.014, respectively). Conclusion: Elevated PD-L1 mRNA expression in lung adenocarcinoma is associated with EGFR mutation and may be mediated through the PI3K-AKT pathway. EGFR exon 19 mutations closely correlate with increased PD-L1 mRNA expression. Increased AKT mRNA expression correlates with lymph node metastasis, while decreased PTEN mRNA levels correlate with advanced tumor stage and lymph node metastasis.
引用
收藏
页码:914 / 920
页数:7
相关论文
共 29 条
[1]
Isoform-specific functions of phosphoinositide 3-kinases:: p110δ but not p110γ promotes optimal allergic responses in vivo [J].
Ali, Khaled ;
Camps, Montserrat ;
Pearce, Wayne P. ;
Ji, Hong ;
Rueckle, Thomas ;
Kuehn, Nicolas ;
Pasquali, Christian ;
Chabert, Christian ;
Rommel, Christian ;
Vanhaesebroeck, Bart .
JOURNAL OF IMMUNOLOGY, 2008, 180 (04) :2538-2544
[2]
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer [J].
Azuma, K. ;
Ota, K. ;
Kawahara, A. ;
Hattori, S. ;
Iwama, E. ;
Harada, T. ;
Matsumoto, K. ;
Takayama, K. ;
Takamori, S. ;
Kage, M. ;
Hoshino, T. ;
Nakanishi, Y. ;
Okamoto, I. .
ANNALS OF ONCOLOGY, 2014, 25 (10) :1935-1940
[3]
Discordant protein and mRNA expression in lung adenocarcinomas [J].
Chen, GA ;
Gharib, TG ;
Huang, CC ;
Taylor, JMG ;
Misek, DE ;
Kardia, SLR ;
Giordano, TJ ;
Iannettoni, MD ;
Orringer, MB ;
Hanash, SM ;
Beer, DG .
MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (04) :304-313
[4]
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [J].
Chen, Nan ;
Fang, Wenfeng ;
Zhan, Jianhua ;
Hong, Shaodong ;
Tang, Yanna ;
Kang, Shiyang ;
Zhang, Yaxiong ;
He, Xiaobo ;
Zhou, Ting ;
Qin, Tao ;
Huang, Yan ;
Yi, Xianping ;
Zhang, Li .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) :910-923
[5]
TOR complex 2: a signaling pathway of its own [J].
Cybulski, Nadine ;
Hall, Michael N. .
TRENDS IN BIOCHEMICAL SCIENCES, 2009, 34 (12) :620-627
[6]
Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
[7]
PHOSPHATIDYLINOSITOL 3-KINASE - STRUCTURE AND EXPRESSION OF THE 110KD CATALYTIC SUBUNIT [J].
HILES, ID ;
OTSU, M ;
VOLINIA, S ;
FRY, MJ ;
GOUT, I ;
DHAND, R ;
PANAYOTOU, G ;
RUIZLARREA, F ;
THOMPSON, A ;
TOTTY, NF ;
HSUAN, JJ ;
COURTNEIDGE, SA ;
PARKER, PJ ;
WATERFIELD, MD .
CELL, 1992, 70 (03) :419-429
[8]
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].
Hodi, F. Stephen ;
O'Day, Steven J. ;
McDermott, David F. ;
Weber, Robert W. ;
Sosman, Jeffrey A. ;
Haanen, John B. ;
Gonzalez, Rene ;
Robert, Caroline ;
Schadendorf, Dirk ;
Hassel, Jessica C. ;
Akerley, Wallace ;
van den Eertwegh, Alfons J. M. ;
Lutzky, Jose ;
Lorigan, Paul ;
Vaubel, Julia M. ;
Linette, Gerald P. ;
Hogg, David ;
Ottensmeier, Christian H. ;
Lebbe, Celeste ;
Peschel, Christian ;
Quirt, Ian ;
Clark, Joseph I. ;
Wolchok, Jedd D. ;
Weber, Jeffrey S. ;
Tian, Jason ;
Yellin, Michael J. ;
Nichol, Geoffrey M. ;
Hoos, Axel ;
Urba, Walter J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723
[9]
Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer [J].
Katso, R ;
Okkenhaug, K ;
Ahmadi, K ;
White, S ;
Timms, J ;
Waterfield, MD .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2001, 17 :615-675
[10]
Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma [J].
Koppolu, Veerendra ;
Vasigala, Veneela Krishna Rekha .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (06) :1167-1175